



- (51) **International Patent Classification:**
A61L 2/18 (2006.01) *A61L 2/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2011/003271
- (22) **International Filing Date:**
23 December 2011 (23.12.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/428,416 30 December 2010 (30.12.2010) US
- (71) **Applicant (for all designated States except US):** **LFB BIOTECHNOLOGIES** [FR/FR]; 3 Avenue Des Tropiques, B.p 305, F-91942 Les Ulis (FR).
- (72) **Inventor; and**
- (75) **Inventor/Applicant (for US only):** **CHTOUROU, Sami** [FR/FR]; 20 Avenue Du Chateau, F-78990 Elancourt (FR).
- (74) **Agent:** **CHAJMOWICZ, Marion**; Cabinet Becker & Associés, 25 rue Louis Le Grand, F-75002 Paris (FR).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** GLYCOLS AS PATHOGEN INACTIVATING AGENTS




Figure 1

(57) **Abstract:** The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.